<DOC>
	<DOC>NCT01793324</DOC>
	<brief_summary>A study to evaluate the effectiveness of an update of educational materials with respect to evaluation of monitoring of metabolic parameters</brief_summary>
	<brief_title>EMR Data to Assess Monitoring of Patients Treated With Quetiapine</brief_title>
	<detailed_description>Objective assessment of metabolic monitoring in patients treated with Seroquel® or Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK and Germany</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Electronic medical records of patients with diagnoses of schizophrenia, Bipolar Disorder (BPD) or Major Depressive Disorder (MDD) treated with Seroquel® or Seroquel®XR during the calendar periods: 13 Feb 31 Aug 2012 seen by GP &amp; psychiatrists in Germany &amp; 11 Jan31 July 2012 seen by GPs in the UK Patients with above mentioned diagnoses treated with Seroquel® or Seroquel® XR/quetiapine fumarate not having any medical encounters during the time periods: 13 Feb 31 Aug 2012 in Germany &amp; 11 Jan31 July 2012 by GPs in the UK</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Effectiveness of risk minimization</keyword>
	<keyword>Metabolic monitoring</keyword>
	<keyword>Seroquel® or Seroquel® XR/quetiapine fumarate</keyword>
</DOC>